Last reviewed · How we verify
REP 2139-Ca
At a glance
| Generic name | REP 2139-Ca |
|---|---|
| Sponsor | Replicor Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B (PHASE2)
- REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection (PHASE2)
- Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REP 2139-Ca CI brief — competitive landscape report
- REP 2139-Ca updates RSS · CI watch RSS
- Replicor Inc. portfolio CI